Belite Bio (BLTE)

Executive Summary

Belite Bio is a clinical-stage biotechnology company developing novel therapies based on its RBP4 (retinol binding protein 4) antagonist platform, with a primary focus on retinal diseases. Its lead asset, tinlarebant (LBS-008), targets Stargardt disease (STGD1) and geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). The company recently completed a Phase 3 trial (NCT05244304) for Stargardt disease in September 2025, with topline data expected in 2026. Additionally, a Phase 3 trial for GA (NCT05949593) is ongoing, with estimated completion in August 2027. Belite’s valuation of ~$5.5 billion reflects the significant unmet need and potential for tinlarebant, which has demonstrated favorable safety and efficacy in earlier studies. The company’s pipeline also includes earlier-stage RBP4 antagonists for liver and metabolic diseases. With a strong intellectual property portfolio and multiple clinical milestones approaching, Belite Bio is well-positioned to deliver transformative treatments for blinding diseases.

Upcoming Catalysts (preview)

• Q2 2026Topline Phase 3 data for tinlarebant in Stargardt disease (NCT05244304)85% success
• H2 2026Interim analysis or update from Phase 3 GA trial (NCT05949593)60% success
• Q1 2027Regulatory submission for tinlarebant in Stargardt disease70% success